This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Xu, Y. Articles by Polychronakos, C. Search for Related Content PubMed PubMed Citation Articles by Xu, Y. Articles by Polychronakos, C. Pubmed/NCBI databases Substance via MeSH

Developmental Regulation of the Soluble Form of Insulin-Like Growth Factor-II/Mannose 6-Phosphate Receptor in Human Serum and Amniotic Fluid¹

Endocrine Genetics Laboratory, the Montreal Children’s Hospital Research Institute, and Department of Pediatrics, McGill University, Montreal, Quebec, Canada H3H 1P3

Address all correspondence and requests for reprints to: Constantin Polychronakos, M.D., F.R.C.P. (C), Endocrinology and Metabolism, Montreal Children’s Hospital, 2300 Tupper Street, Montreal, Quebec, Canada H3H 1P3. E-mail: mc97{at}musica.mcgill.ca

The insulin-like growth factor II/mannose 6-phosphate receptor (IGF-II/MPR) has a specific binding site for IGF-II, a fetal mitogen. In rodents, IGF-II/MPR expression declines dramatically after birth. To see whether such developmental regulation occurs in humans, we studied the ontogeny of the soluble form of IGF-II/MPR in amniotic fluid (AF) and serum. Phosphomannan-affinity purified AF IGF-II/MPR was a single band of approximately 220 kDa, like the band in serum, and it bound IGF-II with affinity identical to that of the membrane-associated form.

By quantitative immunoblot, the soluble IGF-II/MPR in serum and AF was found to undergo developmental regulation that parallels that of the rodent, although it is much less pronounced quantitatively. The highest levels are seen in midgestation, decreasing at term in both serum and AF. In serum, they further decline to one-third of the preterm levels by adulthood.

As part of characterizing AF IGF-II binding, we also show that the prominent high-molecular mass IGF-II-binding protein in preterm AF is GPC3, a protein of the glypican family, recently cloned because its mutations predispose to Wilms’ tumor. For the first time, we show that IGF-II binding to this protein is saturable, and therefore specific. These findings should promote understanding of the role of IGF-II and its binding proteins in human development.

This article has been cited by other articles:

				S. Oesterreicher, W. F. Blum, B. Schmidt, T. Braulke, and B. Kubler Interaction of Insulin-like Growth Factor II (IGF-II) with Multiple Plasma Proteins: HIGH AFFINITY BINDING OF PLASMINOGEN TO IGF-II AND IGF-BINDING PROTEIN-3 J. Biol. Chem., March 18, 2005; 280(11): 9994 - 10000. [Abstract] [Full Text] [PDF]

				C Gicquel, J Weiss, J Amiel, V Gaston, Y Le Bouc, and C D Scott Epigenetic abnormalities of the mannose-6-phosphate/IGF2 receptor gene are uncommon in human overgrowth syndromes J. Med. Genet., January 1, 2004; 41(1): e4 - 4. [Full Text] [PDF]

				S. Zaina, L. Pettersson, A. B. Thomsen, C.-M. Chai, Z. Qi, J. Thyberg, and J. Nilsson Shortened Life Span, Bradycardia, and Hypotension in Mice with Targeted Expression of an Igf2 Transgene in Smooth Muscle Cells Endocrinology, June 1, 2003; 144(6): 2695 - 2703. [Abstract] [Full Text] [PDF]

				H. Yu and T. Rohan Role of the Insulin-Like Growth Factor Family in Cancer Development and Progression J Natl Cancer Inst, September 20, 2000; 92(18): 1472 - 1489. [Abstract] [Full Text] [PDF]

				L. Poretsky, N. A. Cataldo, Z. Rosenwaks, and L. C. Giudice The Insulin-Related Ovarian Regulatory System in Health and Disease Endocr. Rev., August 1, 1999; 20(4): 535 - 582. [Abstract] [Full Text] [PDF]

				M. Costello, R. C. Baxter, and C. D. Scott Regulation of Soluble Insulin-Like Growth Factor II/Mannose 6-Phosphate Receptor in Human Serum: Measurement by Enzyme-Linked Immunosorbent Assay J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 611 - 617. [Abstract] [Full Text]

				J. Y Xuan, R. M Hughes-Benzie, and A. E MacKenzie A small interstitial deletion in the GPC3 gene causes Simpson-Golabi-Behmel syndrome in a Dutch-Canadian family J. Med. Genet., January 1, 1999; 36(1): 57 - 58. [Abstract] [Full Text]

				S. Zaina and S. Squire The Soluble Type 2 Insulin-like Growth Factor (IGF-II) Receptor Reduces Organ Size by IGF-II-mediated and IGF-II-independent Mechanisms J. Biol. Chem., October 30, 1998; 273(44): 28610 - 28616. [Abstract] [Full Text] [PDF]

				S. Zaina, R. V. S. Newton, M. R. Paul, and C. F. Graham Local Reduction of Organ Size in Transgenic Mice Expressing a Soluble Insulin-Like Growth Factor II/Mannose-6-Phosphate Receptor Endocrinology, September 1, 1998; 139(9): 3886 - 3895. [Abstract] [Full Text] [PDF]